EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT ID: NCT01186328

Last Updated: 2024-02-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-24
• Study Completion Date: 2012-01-10

Brief Summary

An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.

Detailed Description

This is a phase I multi-site study of the new investigational agent EZN-3042, which is highly effective at blocking survivin and inhibiting survivin protein expression. Survivin plays pivotal roles in tumor formation by inhibiting cell death and regulating cell cycle progression. The primary objective is to study EZN-3042 in children with relapsed acute lymphoblastic leukemia (ALL). Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine). Blood and bone marrow specimens will be drawn to measure minimal residual disease (MRD), pharmacokinetic levels of EZN-3042 and survivin expression. The study will follow a standard 3+3 dose escalation design. We hypothesize that EZN-3042 will be safe, tolerable and biologically active, when given both alone and in combination with standard re-induction chemotherapy.

Conditions

Lymphoblastic Leukemia, Acute; Lymphoblastic Leukemia, Acute, Childhood; Leukemia, Lymphoblastic, Acute, T Cell; Leukemia, Lymphoblastic, Acute

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).

Group Type: EXPERIMENTAL

EZN-3042

Intervention Type: DRUG

Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg

Cytarabine

Intervention Type: DRUG

Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:

1-1.99 years: 30 mg 2-2.99 years: 50 mg

Greater than or equal to 3 years: 70 mg.

Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:

1. - 1.99 years: 16 mg

2. - 2.99 years: 20 mg

3. - 8.99 years: 24 mg

Greater than or equal to 9 years: 30 mg

Doxorubicin

Intervention Type: DRUG

60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.

Prednisone

Intervention Type: DRUG

40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.

Vincristine

Intervention Type: DRUG

1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.

PEG-asparaginase

Intervention Type: DRUG

2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.

Methotrexate

Intervention Type: DRUG

Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:

1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:

1. - 1.99 years: 8 mg

2. - 2.99 years: 10 mg

3. - 8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Hydrocortisone

Intervention Type: DRUG

Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:

1. - 1.99 years: 8 mg

2. - 2.99 years: 10 mg

3. - 8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Interventions

EZN-3042

Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg

Intervention Type: DRUG

Cytarabine

Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:

1-1.99 years: 30 mg 2-2.99 years: 50 mg

Greater than or equal to 3 years: 70 mg.

Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:

1. - 1.99 years: 16 mg

2. - 2.99 years: 20 mg

3. - 8.99 years: 24 mg

Greater than or equal to 9 years: 30 mg

Intervention Type: DRUG

Doxorubicin

60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.

Intervention Type: DRUG

Prednisone

40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.

Intervention Type: DRUG

Vincristine

1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.

Intervention Type: DRUG

PEG-asparaginase

2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.

Intervention Type: DRUG

Methotrexate

Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:

1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:

1. - 1.99 years: 8 mg

2. - 2.99 years: 10 mg

3. - 8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Intervention Type: DRUG

Hydrocortisone

Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:

1. - 1.99 years: 8 mg

2. - 2.99 years: 10 mg

3. - 8.99 years: 12 mg

Greater than or equal to 9 years: 15 mg

Intervention Type: DRUG

Other Intervention Names

SPC 3042; ARA-C; cytosine arabinoside; Cytosar; Cytosar-U®; Arabinosylcytosine; Adriamycin; Rubex; Prednisone Intensol®; Sterapred®; Sterapred® DS; Predone®; Deltasone®; Oncovin®; vincristine sulfate; Vincasar Pfs®; VCR; LCR; Oncaspar®; PEG-L-asparaginase; Rheumatrex; Trexall; Amethopterin; Methotrexate Sodium; MTX; Ala-Cort ®; Hydrocortone Phosphate; Solu-Cortef®; Hydrocort Acetate®; Lanacort®; Cortef®; Westcort®; Cortisone; Hydrocortisone Sodium Succinate; Hydrocortisone Sodium Phosphate

Eligibility Criteria

Inclusion Criteria

• Patients must be ≥1 and ≤ 21 years of age when originally diagnosed with acute lymphoblastic leukemia (ALL).
• Patients must have relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) with ≥25% blasts in the bone marrow (M3), with or without extramedullary disease.
• Patients may have central nervous system 1, 2 or 3 disease.
• Karnofsky Performance Level ≥ 50 for patients > 10 years of age and Lansky ≥ 50 for patients ≤ 10 years of age.
• Patients must have had 2 or more prior therapeutic attempts defined as:

• Relapse after going into remission from re-induction for the first or subsequent relapse (ie: 2nd , 3rd, 4th…relapse), or
• Refractory disease after first or greater relapse and a single re-induction attempt. *Please note, Enrollment will be restricted to at most one refractory patient in each cohort of 3 patients per dose level.
• Patients with ALL who are refractory to frontline induction therapy are not eligible.
• Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study.
• Patients who relapse when they are not receiving standard ALL maintenance therapy must have fully recovered from grade 3 or 4 toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
• Cytotoxic Therapy: It must be at least 14 days since the completion of cytotoxic therapy (excluding hydroxyurea) at the time of study enrollment.
• Hematopoietic Stem Cell Transplant (HSCT): Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of active Graft-versus-Host Disease (GVHD) and are at least 120 days post-transplant at the time of enrollment.
• Prior anthracycline exposure: Patients must have ≤ 400 mg/m2 lifetime exposure of anthracycline chemotherapy.
• Biologic (anti-neoplastic) therapy: It must be at least 7 days since the completion of therapy with a biologic agent at the time of study enrollment. For agents that have known adverse events occurring 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
• Patients must have a calculated creatinine clearance or radioisotope GRF ≥ 70mL/min/1.73m2 OR a normal serum creatinine based on the institutional normal values according to age.
• Patient's ALT must be < 5 x institutional upper limit of norm (ULN), unless the elevation is suspected to be disease-related.
• Patient's total bilirubin must be ≤ 1.5 x ULN.
• Patient's serum albumin must be ≥ 2 g/dL.
• Patient must have prothrombin time (PT), partial thromboplastin time (PTT) and international normalized ratio (INR) ≤ 1.5 times the ULN.
• Patient must have a shortening fraction ≥ 27% by echocardiogram or an ejection fraction ≥ 45% by gated nucleotide study.
• Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
• Female patients with infants must agree not to breastfeed their infants while on this study.
• Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.

Exclusion Criteria

• Patients with Down syndrome are excluded.
• Patients with B-cell ALL (L3 morphology or evidence of myc translocation by molecular or cytogenetic technique) are not eligible
• Patients who cannot receive asparaginase on this study due to prior pancreatitis, stroke or other toxicity are not eligible.

• Patients with clinically significant prior allergies to PEG asparaginase are eligible if Erwinia L-asparaginase can be substituted. The study will not supply Erwinia.
• Patients who initially receive asparaginase, but must discontinue due to toxicity, remain eligible.
• Patients with documented active and uncontrolled infection at the time of study entry are not eligible.
• Patient will be excluded if they are currently receiving other investigational drugs.
• Patients will be excluded if they are taking strong CYP3A4 inducers or inhibitors.
• Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
• Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Enzon Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: collaborator

Therapeutic Advances in Childhood Leukemia Consortium

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elizabeth Raetz, MD

Role: STUDY_CHAIR

NYU Langone Health

William Carroll, MD

Role: STUDY_CHAIR

NYU Langone Health

Locations

Childrens Hospital Los Angeles

Los Angeles, California, United States

Johns Hopkins University

Baltimore, Maryland, United States

University of Minnesota Children's Hospital

Minneapolis, Minnesota, United States

Childrens Hospital & Clinics of Minnesota

Minneapolis, Minnesota, United States

New York University Medical Center

New York, New York, United States

St. Jude

Memphis, Tennessee, United States

Sydney Children's Hospital

Sydney, , Australia

Countries

United States; Australia

References

Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014 Aug;36(6):458-63. doi: 10.1097/MPH.0b013e3182a8f58f.

Reference Type: RESULT

PMID: 24276047 (View on PubMed)

Related Links

http://www.tacl.us

Therapeutic Advances in Childhood Leukemia \& Lymphoma Consortium web site

Other Identifiers

T2009-007

Identifier Type: -

Identifier Source: org_study_id